2329692-74-0
Chemical Structure
Etevritamab
Synonym(s): AMG-596
- CAS No.: 2329692-74-0
- Formula:N/A
- Molecular Weight:(54.66 kDa)
IUPAC Name: methyl 1-(piperidin-3-yl)-1H-1,2,3-triazole-4-carboxylate
SMILES: [Etevritamab]
Biological Activity: Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Etevritamab | 97.00% | Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sternjak A, et al. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII. Mol Cancer Ther. 2021;20(5):925-933. [Content Brief]
- [2]. Robat-Jazi B, et al. The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma. Clin Exp Med. 2026;26(1):153. Published 2026 Feb 14. [Content Brief]
Keywords
